|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wong YF, Cheung TH, Lo KW, Yim SF, Siu NS,
Chan SC, Ho TW, Wong KW, Yu MY, Wang VW, et al: Identification of
molecular markers and signaling pathway in endometrial cancer in
Hong Kong Chinese women by genome-wide gene expression profiling.
Oncogene. 26:1971–1982. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang Y, Liu Z, Yu X, Zhang X, Lü S, Chen
X and Lü B: The association between metabolic abnormality and
endometrial cancer: A large case-control study in China. Gynecol
Oncol. 117:41–46. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boren T, Xiong Y, Hakam A, Wenham R, Apte
S, Wei Z, Kamath S, Chen DT, Dressman H and Lancaster JM: MicroRNAs
and their target messenger RNAs associated with endometrial
carcinogenesis. Gynecol Oncol. 110:206–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Malumbres M and Barbacid M: Mammalian
cyclin-dependent kinases. Trends Biochem Sci. 30:630–641. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Malumbres M: Cyclin-dependent kinases.
Genome Biol. 15:1222014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shapiro GI: Cyclin-dependent kinase
pathways as targets for cancer treatment. J Clin Oncol.
24:1770–1783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang S and Fischer PM: Cyclin-dependent
kinase 9: A key transcriptional regulator and potential drug target
in oncology, virology and cardiology. Trends Pharmacol Sci.
29:302–313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Franco LC, Morales F, Boffo S and Giordano
A: CDK9: A key player in cancer and other diseases. J Cell Biochem.
119:1273–1284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kohoutek J: P-TEFb- the final frontier.
Cell Div. 4:192009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bagella L, MacLachlan TK, Buono RJ, Pisano
MM, Giordano A and De Luca A: Cloning of murine CDK9/PITALRE and
its tissue-specific expression in development. J Cell Physiol.
177:206–213. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brägelmann J, Dammert MA, Dietlein F,
Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V,
Lorenz C, et al: Systematic kinase inhibitor profiling identifies
CDK9 as a synthetic lethal target in NUT midline carcinoma. Cell
Rep. 20:2833–2845. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rahaman MH, Kumarasiri M, Mekonnen LB, Yu
M, Diab S, Albrecht H, Milne RW and Wang S: Targeting CDK9: A
promising therapeutic opportunity in prostate cancer. Endocr Relat
Cancer. 23:T211–T226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mitra P, Yang RM, Sutton J, Ramsay RG and
Gonda TJ: CDK9 inhibitors selectively target estrogen
receptor-positive breast cancer cells through combined inhibition
of MYB and MCL-1 expression. Oncotarget. 7:9069–9083. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Whittaker SR, Barlow C, Martin MP, Mancusi
C, Wagner S, Self A, Barrie E, Te Poele R, Sharp S, Brown N, et al:
Molecular profiling and combinatorial activity of CCT068127: A
potent CDK2 and CDK9 inhibitor. Mol Oncol. 12:287–304. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baker A, Gregory GP, Verbrugge I, Kats L,
Hilton JJ, Vidacs E, Lee EM, Lock RB, Zuber J, Shortt J, et al: The
CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor
effects in preclinical models of MLL-rearranged acute myeloid
leukemia. Cancer Res. 76:1158–1169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Su YT, Chen R, Wang H, Song H, Zhang Q,
Chen LY, Lappin H, Vasconcelos G, Lita A, Maric D, et al: Novel
targeting of transcription and metabolism in glioblastoma. Clin
Cancer Res. 24:1124–1137. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ajiro M, Sakai H, Onogi H, Yamamoto M,
Sumi E, Sawada T, Nomura T, Kabashima K, Hosoya T and Hagiwara M:
CDK9 inhibitor FIT-039 suppresses viral oncogenes E6 and E7 and has
a therapeutic effect on HPV-induced neoplasia. Clin Cancer Res.
24:4518–4528. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Albert TK, Rigault C, Eickhoff J, Baumgart
K, Antrecht C, Klebl B, Mittler G and Meisterernst M:
Characterization of molecular and cellular functions of the
cyclin-dependent kinase CDK9 using a novel specific inhibitor. Br J
Pharmacol. 171:55–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baranyi U, Winter B, Gugerell A, Hegedus
B, Brostjan C, Laufer G and Messner B: Primary human fibroblasts in
culture switch to a myofibroblast-like phenotype independently of
TGF beta. Cells. 8:7212019. View Article : Google Scholar
|
|
22
|
Lay V, Yap J, Sonderegger S and
Dimitriadis E: Interleukin 11 regulates endometrial cancer cell
adhesion and migration via STAT3. Int J Oncol. 41:759–764. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
De U, Son JY, Sachan R, Park YJ, Kang D,
Yoon K, Lee BM, Kim IS, Moon HR and Kim HS: A new synthetic histone
deacetylase inhibitor, MHY2256, induces apoptosis and autophagy
cell death in endometrial cancer cells via p53 acetylation. Int J
Mol Sci. 19:27432018. View Article : Google Scholar
|
|
24
|
Espedal H, Fonnes T, Fasmer KE, Krakstad C
and Haldorsen IS: Imaging of preclinical endometrial cancer models
for monitoring tumor progression and response to targeted therapy.
Cancers (Basel). 11:18852019. View Article : Google Scholar
|
|
25
|
Gueli Alletti S, Rossitto C, Cianci S,
Restaino S, Costantini B, Fanfani F, Fagotti A, Cosentino F and
Scambia G: Telelap ALF-X vs standard laparoscopy for the treatment
of early-stage endometrial cancer: A single-institution
retrospective cohort study. J Minim Invasive Gynecol. 23:378–383.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scaletta G, Dinoi G, Capozzi V, Cianci S,
Pelligra S, Ergasti R, Fagotti A, Scambia G and Fanfani F:
Comparison of minimally invasive surgery with laparotomic approach
in the treatment of high risk endometrial cancer: A systematic
review. Eur J Surg Oncol. 46:782–788. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rossitto C, Cianci S, Gueli Alletti S,
Perrone E, Pizzacalla S and Scambia G: Laparoscopic,
minilaparoscopic, single-port and percutaneous hysterectomy:
Comparison of perioperative outcomes of minimally invasive
approaches in gynecologic surgery. Eur J Obstet Gynecol Reprod
Biol. 216:125–129. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang H, Pandey S, Travers M, Sun H,
Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA,
et al: Targeting CDK9 reactivates epigenetically silenced genes in
cancer. Cell. 175:1244–1258.e26. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang J, Dean DC, Hornicek FJ, Shi H and
Duan Z: Cyclin- dependent kinase 9 (CDK9) is a novel prognostic
marker and therapeutic target in ovarian cancer. FASEB J.
33:5990–6000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ramdass B, Maliekal TT, Lakshmi S, Rehman
M, Rema P, Nair P, Mukherjee G, Reddy BK, Krishna S and
Radhakrishna Pillai M: Coexpression of Notch1 and NF-kappaB
signaling pathway components in human cervical cancer progression.
Gynecol Oncol. 104:352–361. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Romano G: Deregulations in the
cyclin-dependent kinase-9- related pathway in cancer: Implications
for drug discovery and development. ISRN Oncol.
2013:3053712013.PubMed/NCBI
|
|
32
|
Lu H, Xue Y, Yu GK, Arias C, Lin J, Fong
S, Faure M, Weisburd B, Ji X, Mercier A, et al: Compensatory
induction of MYC expression by sustained CDK9 inhibition via a
BRD4-dependent mechanism. Elife. 4:e065352015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yin T, Lallena MJ, Kreklau EL, Fales KR,
Carballares S, Torrres R, Wishart GN, Ajamie RT, Cronier DM,
Iversen PW, et al: A novel CDK9 inhibitor shows potent antitumor
efficacy in preclinical hematologic tumor models. Mol Cancer Ther.
13:1442–1456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Caracciolo V, Laurenti G, Romano G,
Carnevale V, Cimini AM, Crozier-Fitzgerald C, Gentile Warschauer E,
Russo G and Giordano A: Flavopiridol induces phosphorylation of AKT
in a human glioblastoma cell line, in contrast to siRNA-mediated
silencing of Cdk9: Implications for drug design and development.
Cell Cycle. 11:1202–1216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Walsby E, Pratt G, Shao H, Abbas AY,
Fischer PM, Bradshaw TD, Brennan P, Fegan C, Wang S and Pepper C: A
novel Cdk9 inhibitor preferentially targets tumor cells and
synergizes with fludarabine. Oncotarget. 5:375–385. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rajput S, Khera N, Guo Z, Hoog J, Li S and
Ma CX: Inhibition of cyclin dependent kinase 9 by dinaciclib
suppresses cyclin B1 expression and tumor growth in triple negative
breast cancer. Oncotarget. 7:56864–56875. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang CH, Lujambio A, Zuber J,
Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de
Stanchina E, Sawyers CL, et al: CDK9-mediated transcription
elongation is required for MYC addiction in hepatocellular
carcinoma. Genes Dev. 28:1800–1814. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fassl A and Sicinski P: Chemotherapy and
CDK4/6 inhibition in cancer treatment: Timing is everything. Cancer
Cell. 37:265–267. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin CY, Lee LY, Wang TH, Hsu CL, Tsai CL,
Chao A and Lai CH: Palbociclib promotes dephosphorylation of
NPM/B23 at threonine 199 and inhibits endometrial cancer cell
growth. Cancers (Basel). 11:10252019. View Article : Google Scholar
|
|
40
|
Morales F and Giordano A: Overview of CDK9
as a target in cancer research. Cell Cycle. 15:519–527. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ma H, Seebacher NA, Hornicek FJ and Duan
Z: Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker
and therapeutic target in osteosarcoma. EBioMedicine. 39:182–193.
2019. View Article : Google Scholar : PubMed/NCBI
|
